Her2-targeting antibody-drug conjugate rc48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study

HIGHLIGHTS

• who: Meiting Chen from the Guangzhou, China have published the paper: HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study, in the Journal: (JOURNAL) of August/10,/2022
• what: This study evaluated verses in combination with for locally advanced or metastatic UC using real-world data.
• how: The results showed that RC48 alone or combined with immunotherapy showed excellent antitumor activity in patients with locally advanced or metastatic UC.
• future: Exploration in the future study was . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.